The estimated Net Worth of Jeffrey Kenneth Vogel is at least $51 Milion dollars as of 28 October 2015. Jeffrey Vogel owns over 11,196 units of Biospecifics Technologies stock worth over $45,031,316 and over the last 33 years Jeffrey sold BSTC stock worth over $5,935,175.
Sign up
Jeffrey Vogel BSTC stock SEC Form 4 insiders trading
Jeffrey has made over 7 trades of the Biospecifics Technologies stock since 1991, according to the Form 4 filled with the SEC. Most recently Jeffrey bought 11,196 units of BSTC stock worth $546,141 on 28 October 2015.
The largest trade Jeffrey's ever made was buying 181,658 units of Biospecifics Technologies stock on 12 April 2012 worth over $2,557,745. On average, Jeffrey trades about 57,009 units every 1,265 days since 1991. As of 28 October 2015 Jeffrey still owns at least 508,656 units of Biospecifics Technologies stock.
You can see the complete history of Jeffrey Vogel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jeffrey Vogel's mailing address?
Jeffrey's mailing address filed with the SEC is 1 MEADOW DRIVE, , LAWRENCE, NY, 11559.
Insiders trading at Biospecifics Technologies
Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo oraz Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.
What does Biospecifics Technologies's logo look like?
Complete history of Jeffrey Vogel stock trades at Biospecifics Technologies
Biospecifics Technologies executives and stock owners
Biospecifics Technologies executives and other stock owners filed with the SEC include:
-
Jennifer Chao,
Independent Chairman of the Board -
Michael Schamroth,
Independent Director -
Paul Gitman,
Independent Director -
Mark Wegman,
Director -
Toby Wegman,
Director -
Sarah McCabe,
Stern Investor Relations -
Michael Sherman,
Independent Director -
Corey Fishman,
Independent Director -
Alex Monteith,
Senior Vice President and Chief Business Officer -
Patrick Hutchison,
Chief Financial Officer -
Joseph Truitt,
Chief Executive Officer, Director -
Jeffrey Kenneth Vogel,
-
Jyrki Mattila,
Director -
Thomas Wegman,
President -
Of Edwin H. Wegman Estate,
10% owner -
Patrick M Caldwell,
Principal Financial Officer -
Partners Lp Bio,
10% owner -
Albert Horcher,
-
Lawrence Dobroff,
CFO -
Max Link,
Director -
Henry Morgan,
Director -
George M Gould,
Director -
Matthew Geller,
Director -
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
Capital Management, Llcaldr...,
-
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
J Kevin Buchi,
Chief Executive Officer -
International Plc Endo,
10% owner